Skip to main content
. 2017 Jan;91(1):39–47. doi: 10.1124/mol.116.106666

Fig. 2.

Fig. 2.

Inhibition of PAR1 and PAR4 abolish thrombin-mediated signaling on human platelets. (A) The effect of PAR1 and PAR4 antagonists individually on thrombin-mediated platelet activation. Platelets were treated with increasing doses of SCH602539 or VU0652925 for 20 minutes prior to activation with 2 or 10 nM α-thrombin. GPIIbIIIa activation was monitored by PAC1 binding. Means ± S.E.M. are shown (n = 4). (B) The effect of PAR1 and PAR4 antagonists, combined, on platelet activation by thrombin. Platelets were treated for 20 minutes with 3.16 μM SCH62539 or 1 μM VU652965 prior to activation with 2 or 10 nM α-thrombin. Means ± S.E.M. are shown (n = 3). Two-sided t-test was used. Software used was GraphPad Prism (GraphPad Software, La Jolla, CA). *, P < 0.05; ***, P < 0.005. (C) The effect of PAR1 and PAR4 antagonists on platelet aggregation induced by thrombin. Platelets were pretreated for 20 minutes with antagonist prior to activation with 10 nM α-thrombin. Representative tracings of three independent experiments are shown. DMSO, dimethylsulfoxide.